Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tandem Mass Spectrometry | 13 | 2021 | 227 | 3.690 |
Why?
|
| Chromatography, High Pressure Liquid | 18 | 2021 | 338 | 3.010 |
Why?
|
| Riluzole | 8 | 2023 | 21 | 2.270 |
Why?
|
| Paclitaxel | 6 | 2020 | 121 | 2.050 |
Why?
|
| Spinal Cord Injuries | 7 | 2023 | 311 | 1.970 |
Why?
|
| Neuroprotective Agents | 6 | 2023 | 150 | 1.700 |
Why?
|
| Gastric Bypass | 3 | 2019 | 69 | 1.300 |
Why?
|
| Mycophenolic Acid | 3 | 2017 | 51 | 1.230 |
Why?
|
| Immunosuppressive Agents | 3 | 2017 | 644 | 0.940 |
Why?
|
| Polyethylene Glycols | 7 | 2019 | 217 | 0.910 |
Why?
|
| Cervical Cord | 1 | 2023 | 9 | 0.880 |
Why?
|
| Neck Injuries | 1 | 2023 | 23 | 0.870 |
Why?
|
| Veratrum Alkaloids | 2 | 2019 | 10 | 0.830 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2023 | 145 | 0.770 |
Why?
|
| Camptothecin | 2 | 2019 | 76 | 0.760 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2007 | 102 | 0.700 |
Why?
|
| Plasma | 2 | 2017 | 96 | 0.680 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 2842 | 0.650 |
Why?
|
| Obesity, Morbid | 2 | 2019 | 184 | 0.650 |
Why?
|
| Chromatography, Liquid | 6 | 2021 | 191 | 0.640 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2017 | 1197 | 0.630 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 24 | 0.620 |
Why?
|
| Bile | 1 | 2018 | 46 | 0.610 |
Why?
|
| Polymyxin B | 6 | 2015 | 44 | 0.610 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2018 | 96 | 0.590 |
Why?
|
| Drug Combinations | 1 | 2018 | 271 | 0.580 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 93 | 0.570 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 173 | 0.550 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 67 | 0.500 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 714 | 0.500 |
Why?
|
| Arginine Vasopressin | 1 | 2014 | 28 | 0.460 |
Why?
|
| Rats | 9 | 2021 | 3654 | 0.460 |
Why?
|
| Calcium Chloride | 1 | 2014 | 22 | 0.460 |
Why?
|
| Prodrugs | 3 | 2019 | 59 | 0.450 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2021 | 1215 | 0.450 |
Why?
|
| Hypnotics and Sedatives | 1 | 2015 | 134 | 0.440 |
Why?
|
| Limit of Detection | 3 | 2019 | 60 | 0.430 |
Why?
|
| Epinephrine | 1 | 2014 | 174 | 0.420 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 269 | 0.410 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 135 | 0.410 |
Why?
|
| Drug Stability | 6 | 2018 | 55 | 0.410 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 452 | 0.390 |
Why?
|
| Intensive Care Units | 1 | 2015 | 482 | 0.370 |
Why?
|
| Animals | 25 | 2021 | 33761 | 0.360 |
Why?
|
| Administration, Oral | 5 | 2021 | 671 | 0.340 |
Why?
|
| Copper Radioisotopes | 2 | 2019 | 6 | 0.330 |
Why?
|
| Half-Life | 6 | 2021 | 156 | 0.330 |
Why?
|
| Length of Stay | 1 | 2015 | 1285 | 0.320 |
Why?
|
| Biological Availability | 5 | 2021 | 128 | 0.320 |
Why?
|
| Pancreatic Neoplasms | 3 | 2019 | 673 | 0.310 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 211 | 0.300 |
Why?
|
| Calibration | 2 | 2018 | 88 | 0.300 |
Why?
|
| Chemistry, Pharmaceutical | 4 | 2014 | 45 | 0.300 |
Why?
|
| Neoplasms | 2 | 2021 | 2758 | 0.290 |
Why?
|
| Hemolysis | 1 | 2007 | 105 | 0.280 |
Why?
|
| Obesity | 1 | 2018 | 2227 | 0.280 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2017 | 42 | 0.280 |
Why?
|
| Temperature | 3 | 2018 | 306 | 0.270 |
Why?
|
| Tissue Distribution | 4 | 2019 | 382 | 0.270 |
Why?
|
| Male | 19 | 2023 | 60117 | 0.260 |
Why?
|
| Biological Assay | 2 | 2017 | 100 | 0.260 |
Why?
|
| Spinal Cord | 2 | 2018 | 305 | 0.260 |
Why?
|
| Solubility | 6 | 2007 | 132 | 0.260 |
Why?
|
| Infusions, Intravenous | 4 | 2016 | 536 | 0.260 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 1661 | 0.240 |
Why?
|
| Liposomes | 2 | 2018 | 168 | 0.240 |
Why?
|
| Cell Survival | 1 | 2007 | 806 | 0.240 |
Why?
|
| Etoposide | 2 | 1999 | 117 | 0.240 |
Why?
|
| Humans | 30 | 2023 | 123213 | 0.230 |
Why?
|
| Middle Aged | 10 | 2023 | 26009 | 0.220 |
Why?
|
| Injections, Intravenous | 4 | 2018 | 252 | 0.210 |
Why?
|
| Weight Loss | 2 | 2019 | 478 | 0.210 |
Why?
|
| Reference Standards | 3 | 2016 | 240 | 0.210 |
Why?
|
| Solvents | 3 | 2018 | 42 | 0.210 |
Why?
|
| Sodium Chloride | 2 | 2014 | 95 | 0.200 |
Why?
|
| Nanoparticles | 2 | 2019 | 231 | 0.190 |
Why?
|
| Busulfan | 2 | 2000 | 44 | 0.190 |
Why?
|
| Kenya | 1 | 2021 | 51 | 0.190 |
Why?
|
| Dried Blood Spot Testing | 1 | 2021 | 22 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 5 | 2015 | 2396 | 0.190 |
Why?
|
| Vincristine | 1 | 2021 | 195 | 0.180 |
Why?
|
| Calcitriol | 1 | 2020 | 80 | 0.180 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2018 | 15 | 0.180 |
Why?
|
| Administration, Intravenous | 2 | 2018 | 143 | 0.170 |
Why?
|
| Time Factors | 6 | 2021 | 6217 | 0.170 |
Why?
|
| Excipients | 3 | 2010 | 11 | 0.170 |
Why?
|
| Infant, Premature | 2 | 2015 | 798 | 0.160 |
Why?
|
| Exosomes | 1 | 2019 | 41 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2015 | 1388 | 0.160 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 288 | 0.160 |
Why?
|
| Adult | 9 | 2019 | 29091 | 0.160 |
Why?
|
| Propylene Glycol | 1 | 2018 | 8 | 0.160 |
Why?
|
| Rosuvastatin Calcium | 1 | 2018 | 41 | 0.160 |
Why?
|
| Preoperative Period | 1 | 2018 | 82 | 0.150 |
Why?
|
| Lactones | 1 | 2018 | 39 | 0.150 |
Why?
|
| Copper | 1 | 2018 | 62 | 0.150 |
Why?
|
| Glycerol | 1 | 2018 | 91 | 0.150 |
Why?
|
| Simvastatin | 1 | 2018 | 75 | 0.150 |
Why?
|
| Metal Nanoparticles | 1 | 2018 | 42 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 77 | 0.150 |
Why?
|
| Female | 17 | 2019 | 65516 | 0.150 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 29 | 0.150 |
Why?
|
| Serpins | 1 | 2018 | 27 | 0.150 |
Why?
|
| Liquid-Liquid Extraction | 1 | 2017 | 10 | 0.150 |
Why?
|
| Nerve Growth Factors | 1 | 2018 | 72 | 0.150 |
Why?
|
| Mice | 11 | 2019 | 17496 | 0.150 |
Why?
|
| Postoperative Period | 1 | 2018 | 330 | 0.140 |
Why?
|
| Emulsions | 2 | 2007 | 65 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 4348 | 0.140 |
Why?
|
| Drug Design | 1 | 2018 | 146 | 0.140 |
Why?
|
| Linear Models | 1 | 2019 | 669 | 0.140 |
Why?
|
| Acetates | 1 | 2017 | 71 | 0.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1997 | 99 | 0.140 |
Why?
|
| Stromal Cells | 1 | 2018 | 294 | 0.140 |
Why?
|
| Pharmaceutical Solutions | 2 | 2014 | 8 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 148 | 0.140 |
Why?
|
| Cholesterol | 1 | 2019 | 525 | 0.140 |
Why?
|
| Anisoles | 1 | 2016 | 1 | 0.130 |
Why?
|
| Eye Proteins | 1 | 2018 | 218 | 0.130 |
Why?
|
| Atmospheric Pressure | 1 | 2016 | 5 | 0.130 |
Why?
|
| Solid Phase Extraction | 1 | 2016 | 2 | 0.130 |
Why?
|
| Serum Albumin | 1 | 2016 | 107 | 0.130 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2018 | 244 | 0.130 |
Why?
|
| Glucuronides | 1 | 2016 | 24 | 0.130 |
Why?
|
| Laser Therapy | 1 | 2018 | 246 | 0.130 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 557 | 0.130 |
Why?
|
| Lipopolysaccharides | 2 | 2019 | 290 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1310 | 0.120 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2015 | 29 | 0.120 |
Why?
|
| Body Temperature Regulation | 1 | 2015 | 30 | 0.120 |
Why?
|
| Antiemetics | 1 | 2014 | 23 | 0.120 |
Why?
|
| Area Under Curve | 3 | 2019 | 313 | 0.120 |
Why?
|
| Respiratory Mechanics | 1 | 2015 | 75 | 0.120 |
Why?
|
| Inflammation | 2 | 2019 | 1402 | 0.120 |
Why?
|
| Sus scrofa | 1 | 2015 | 122 | 0.120 |
Why?
|
| Drug Packaging | 1 | 2014 | 7 | 0.120 |
Why?
|
| Spectrophotometry | 1 | 2014 | 58 | 0.110 |
Why?
|
| Drug Compounding | 1 | 2014 | 34 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 714 | 0.110 |
Why?
|
| Humidity | 1 | 2014 | 23 | 0.110 |
Why?
|
| Species Specificity | 1 | 2015 | 549 | 0.110 |
Why?
|
| Dopamine | 1 | 2015 | 275 | 0.110 |
Why?
|
| Particle Size | 2 | 2019 | 116 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 2390 | 0.110 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 3273 | 0.110 |
Why?
|
| Delayed-Action Preparations | 2 | 2019 | 110 | 0.110 |
Why?
|
| Models, Animal | 1 | 2015 | 464 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2017 | 542 | 0.100 |
Why?
|
| Teichoic Acids | 1 | 2012 | 13 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2023 | 6033 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 77 | 0.100 |
Why?
|
| Body Fluids | 1 | 2013 | 48 | 0.100 |
Why?
|
| Midazolam | 1 | 2012 | 49 | 0.100 |
Why?
|
| Anesthetics, Intravenous | 1 | 2012 | 47 | 0.100 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 114 | 0.100 |
Why?
|
| Double-Blind Method | 3 | 2023 | 1589 | 0.100 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2012 | 59 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 629 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2018 | 830 | 0.090 |
Why?
|
| Cell Proliferation | 4 | 2019 | 2306 | 0.090 |
Why?
|
| Aged | 4 | 2019 | 19089 | 0.090 |
Why?
|
| Infant | 2 | 2016 | 12347 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2019 | 695 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2016 | 13888 | 0.080 |
Why?
|
| Adolescent | 4 | 2016 | 19124 | 0.080 |
Why?
|
| Pentetic Acid | 2 | 2006 | 10 | 0.080 |
Why?
|
| In Vitro Techniques | 2 | 2007 | 966 | 0.080 |
Why?
|
| Child | 2 | 2021 | 24244 | 0.080 |
Why?
|
| Oils | 1 | 2007 | 6 | 0.070 |
Why?
|
| Young Adult | 3 | 2016 | 8886 | 0.070 |
Why?
|
| Surface-Active Agents | 1 | 2007 | 31 | 0.070 |
Why?
|
| Nicotinic Acids | 1 | 2006 | 7 | 0.070 |
Why?
|
| Quinine | 1 | 1986 | 7 | 0.070 |
Why?
|
| Ochronosis | 1 | 1986 | 2 | 0.070 |
Why?
|
| Brain | 1 | 2018 | 2962 | 0.070 |
Why?
|
| Niacin | 1 | 2006 | 57 | 0.070 |
Why?
|
| Nonprescription Drugs | 1 | 2006 | 46 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 229 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 4276 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2006 | 118 | 0.060 |
Why?
|
| Skin Absorption | 1 | 1984 | 7 | 0.060 |
Why?
|
| Indoles | 1 | 2006 | 180 | 0.060 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 176 | 0.060 |
Why?
|
| Triamcinolone Acetonide | 1 | 1984 | 36 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8107 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1530 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 260 | 0.060 |
Why?
|
| Azepines | 1 | 1984 | 61 | 0.060 |
Why?
|
| Annexin A5 | 1 | 2003 | 15 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1997 | 425 | 0.050 |
Why?
|
| Cervical Vertebrae | 2 | 2013 | 107 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 57 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 142 | 0.050 |
Why?
|
| Suspensions | 1 | 2019 | 9 | 0.040 |
Why?
|
| Drug Liberation | 1 | 2019 | 11 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2019 | 16 | 0.040 |
Why?
|
| 2-Propanol | 1 | 1999 | 3 | 0.040 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 1999 | 6 | 0.040 |
Why?
|
| Spectrophotometry, Infrared | 1 | 1999 | 20 | 0.040 |
Why?
|
| Microscopy, Polarization | 1 | 1999 | 10 | 0.040 |
Why?
|
| Melanoma | 1 | 2006 | 824 | 0.040 |
Why?
|
| Crystallization | 1 | 1999 | 83 | 0.040 |
Why?
|
| Peptides, Cyclic | 1 | 2018 | 52 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 94 | 0.040 |
Why?
|
| Micelles | 1 | 2018 | 19 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 1997 | 51 | 0.040 |
Why?
|
| Solutions | 1 | 1997 | 65 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 556 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2000 | 323 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2019 | 356 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1683 | 0.040 |
Why?
|
| Polymers | 1 | 2018 | 106 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 350 | 0.030 |
Why?
|
| Water | 1 | 1997 | 182 | 0.030 |
Why?
|
| Apoptosis | 1 | 2003 | 1781 | 0.030 |
Why?
|
| Dogs | 1 | 1997 | 765 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2000 | 286 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 1005 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 740 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 1441 | 0.030 |
Why?
|
| Kinetics | 2 | 2010 | 1314 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1104 | 0.030 |
Why?
|
| Polymyxins | 1 | 2015 | 14 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 1002 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 864 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 1001 | 0.030 |
Why?
|
| Gels | 1 | 2014 | 60 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 130 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2013 | 30 | 0.030 |
Why?
|
| Drug Contamination | 2 | 2010 | 36 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2023 | 12134 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2013 | 66 | 0.030 |
Why?
|
| Serum | 1 | 2013 | 46 | 0.030 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2013 | 47 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 94 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 1227 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 90 | 0.030 |
Why?
|
| Uremia | 1 | 1983 | 35 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 151 | 0.030 |
Why?
|
| Ibuprofen | 1 | 1983 | 42 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 2022 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2012 | 28 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 2012 | 86 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2013 | 359 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 164 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 1740 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2013 | 438 | 0.020 |
Why?
|
| Bordetella bronchiseptica | 1 | 2010 | 2 | 0.020 |
Why?
|
| Refrigeration | 1 | 2010 | 10 | 0.020 |
Why?
|
| Drug Storage | 1 | 2010 | 17 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 414 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 1472 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 522 | 0.020 |
Why?
|
| Chemistry, Physical | 1 | 1989 | 31 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1989 | 84 | 0.020 |
Why?
|
| Salicylates | 1 | 1979 | 53 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 1339 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1496 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 1541 | 0.020 |
Why?
|
| Aspirin | 1 | 1979 | 224 | 0.020 |
Why?
|
| Elastic Tissue | 1 | 1986 | 19 | 0.020 |
Why?
|
| Indium Radioisotopes | 1 | 2006 | 10 | 0.020 |
Why?
|
| Molecular Probe Techniques | 1 | 2006 | 23 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 1986 | 192 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1983 | 842 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 105 | 0.020 |
Why?
|
| Malaria | 1 | 1986 | 82 | 0.020 |
Why?
|
| Lung | 1 | 2013 | 1475 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 253 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 4493 | 0.020 |
Why?
|
| United States | 2 | 2013 | 10633 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2006 | 319 | 0.020 |
Why?
|
| Mice, Hairless | 1 | 1984 | 30 | 0.020 |
Why?
|
| Membranes, Artificial | 1 | 1984 | 27 | 0.020 |
Why?
|
| Diffusion | 1 | 1984 | 58 | 0.020 |
Why?
|
| Silicone Elastomers | 1 | 1984 | 35 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 330 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 3718 | 0.010 |
Why?
|
| Radioisotopes | 1 | 2003 | 38 | 0.010 |
Why?
|
| Skin | 1 | 1986 | 505 | 0.010 |
Why?
|
| Acetamides | 1 | 2000 | 49 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2000 | 98 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 2000 | 190 | 0.010 |
Why?
|
| Safety | 1 | 2000 | 217 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 419 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2013 | 16019 | 0.010 |
Why?
|
| Ultrafiltration | 1 | 1983 | 12 | 0.010 |
Why?
|
| Absorption | 1 | 1983 | 52 | 0.010 |
Why?
|
| Veins | 1 | 1983 | 106 | 0.010 |
Why?
|
| Arteries | 1 | 1983 | 222 | 0.010 |
Why?
|
| Flame Ionization | 1 | 1979 | 1 | 0.010 |
Why?
|
| Methods | 1 | 1979 | 147 | 0.010 |
Why?
|
| Tablets | 1 | 1979 | 28 | 0.010 |
Why?
|